GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Capex-to-Operating-Cash-Flow

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

China SXT Pharmaceuticals's Capital Expenditure for the six months ended in Sep. 2023 was $0.00 Mil. Its Cash Flow from Operations for the six months ended in Sep. 2023 was $-0.58 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


China SXT Pharmaceuticals Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Capex-to-Operating-Cash-Flow Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial 2.55 0.44 - 0.23 -

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.07 - 0.11 -

Competitive Comparison of China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow falls into.



China SXT Pharmaceuticals Capex-to-Operating-Cash-Flow Calculation

China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.071) / -0.081
=N/A

China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.58
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China SXT Pharmaceuticals  (NAS:SXTC) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


China SXT Pharmaceuticals Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Headlines

From GuruFocus

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

By GuruFocusNews GuruFocusNews 06-07-2022

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

By GuruFocusNews GuruFocusNews 05-18-2022

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

By GuruFocusNews GuruFocusNews 05-28-2022